Cancer risk among elderly persons with end-stage renal disease: a population-based case–control study

BMC Nephrology

Eric A Engels²  Paul W Eggers¹  Joan L Warren³  Fatma M Shebl⁴ 

[1] Kidney and Urology Epidemiology Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA;Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA;Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

关键词: Cancer;    Dialysis;    ESKD;    ESRD;    End-Stage Renal Disease;   

Others  :  1083148
DOI  :  10.1186/1471-2369-13-65

 received in 2012-04-25, accepted in 2012-07-11,  发布年份 2012

【 摘 要 】

Background

Patients with end-stage renal disease (ESRD) have elevated cancer risk. Cancer risk increases with age, but associations of ESRD with specific malignancies are incompletely studied for older individuals.

Methods

We conducted a population-based case–control study (1,029,695 cancer and 99,610 controls) among the U.S. elderly using SEER-Medicare linked data. We defined ESRD as presence of dialysis claims in the 3 months prior to selection.

Results

Although ESRD was not associated with excess cancer risk overall (odds ratio 1.02; 95%CI 0.91-1.14), risk was specifically increased for cancers of the stomach (1.45; 1.16-1.81), small intestine (1.92; 1.27-2.92), colon (1.17; 1.00-1.36), liver (1.53; 1.16-2.01), biliary tract (1.78; 1.20-2.65), lung (1.17; 1.02-1.34), cervix (2.12; 1.39-3.23), kidney (2.42; 2.01-2.92), and for multiple myeloma (1.77; 1.40-2.24) and chronic myeloid leukemia (1.74; 1.08-2.80). The association between liver cancer and ESRD was attenuated upon adjustment for hepatitis B and C infection or diabetes mellitus. Multiple myeloma risk was highest with short ESRD duration (p < 0.0001), possibly reflecting reverse causality, while kidney cancer risk showed a borderline rise over time (p = 0.08).

Conclusions

Among elderly individuals with ESRD, the excess risks for some cancers may reflect immune dysfunction or a high prevalence of other risk factors, such as viral infections or diabetes mellitus. Our results underscore the need for studying biological pathways of carcinogenesis in ESRD.

【 授权许可】

   
2012 Shebl et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Betheda, MD; 2011.
• [2]Descamps-Latscha B: The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993, 2(6):883-891.
• [3]Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008, 3(5):1526-1533.
• [4]Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS: Increased incidence of malignancy during chronic renal failure. Lancet 1975, 1(7912):883-886.
• [5]Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, et al.: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999, 354(9173):93-99.
• [6]Inamoto H, Ozaki R, Matsuzaki T, Wakui M, Saruta T, Osawa A: Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients. Nephron 1991, 59(4):611-617.
• [7]Cengiz K: Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002, 33(1):121-126.
• [8]Mandayam S, Shahinian VB: Are chronic dialysis patients at increased risk for cancer? J Nephrol 2008, 21(2):166-174.
• [9]Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P: Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003, 14(1):197-207.
• [10]Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MR: The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009, 24(10):3225-3231.
• [11]Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF: Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40(8):3-18.
• [12]Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL: Use of surveillance, epidemiology, and end results-medicare data to conduct case–control studies of cancer among the US elderly. Am J Epidemiol 2011, 174(7):860-870.
• [13]Taneja S, Mandayam S, Kayani ZZ, Kuo YF, Shahinian VB: Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population. Clin J Am Soc Nephrol 2007, 2(5):1008-1013.
• [14]Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE: Cancer incidence before and after kidney transplantation. JAMA 2006, 296(23):2823-2831.
• [15]Birkeland SA, Lokkegaard H, Storm HH: Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000, 355(9218):1886-1887.
• [16]Ishikawa I, Saito Y, Shikura N, Kitada H, Shinoda A, Suzuki S: Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 1990, 16(5):452-458.
• [17]Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004, 24(5):503-510.
• [18]Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, Takahashi K, Palmer IS, Cohen HJ: Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994, 266(2 Pt 1):C367-375.
• [19]Bonomini M, Forster S, De Risio F, Rychly J, Nebe B, Manfrini V, Klinkmann H, Albertazzi A: Effects of selenium supplementation on immune parameters in chronic uraemic patients on haemodialysis. Nephrol Dial Transplant 1995, 10(9):1654-1661.
• [20]Yoshimura S, Suemizu H, Nomoto Y, Sakai H, Katsuoka Y, Kawamura N, Moriuchi T: Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron 1996, 73(2):207-211.
• [21]Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, Sandler RS: Selenium, folate, and colon cancer. Nutr Cancer 2009, 61(2):165-178.
• [22]Lange JH: Reanalysis of epidemiological data for selenium anti-cancer activity. Toxicol Ind Health 1991, 7(4):319-325.
• [23]Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL: A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007, 99(14):1120-1129.
• [24]Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L: The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim Biophys Acta 2010, 1806(1):82-95.
• [25]Fabrizi F, Bunnapradist S, Martin P: HBV infection in patients with end-stage renal disease. Semin Liver Dis 2004, 24(Suppl 1):63-70.
• [26]de Medina M, Ashby M, Schluter V, Hill M, Leclerq B, Pennell JP, Jeffers LJ, Reddy KR, Schiff ER, Hess G, et al.: Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients. Am J Kidney Dis 1998, 31(2):224-226.
• [27]Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE: Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002, 51(3):429-433.
• [28]Fairley CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker R, Atkins RC, Thomson N, Allan P, Woodburn C, et al.: Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Nephrol Dial Transplant 1994, 9(4):416-420.
• [29]Bengtsson U, Angervall L, Ekman H, Lehmann L: Transitional cell tumors of the renal pelvis in analgesic abusers. Scand J Urol Nephrol 1968, 2(3):145-150.
• [30]Johansson S, Angervall L, Bengtsson U, Wahlqvist L: Uroepithelial tumors of the renal pelvis associated with abuse of phenacetin-containing analgesics. Cancer 1974, 33(3):743-753.
• [31]Bonsib SM: Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol 2009, 4(12):1998-2007.
• [32]Hajj P, Ferlicot S, Massoud W, Awad A, Hammoudi Y, Charpentier B, Durrbach A, Droupy S, Benoit G: Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology 2009, 74(3):631-634.
• [33]Grantham JJ: Polycystic kidney disease: neoplasia in disguise. Am J Kidney Dis 1990, 15(2):110-116.
• [34]Ekart R, Hojs R: Acquired cystic kidney disease and arterial hypertension in hemodialysis patients. Wien Klin Wochenschr 2006, 118(Suppl 2):17-22.
• [35]Ishikawa I: Acquired cysts and neoplasms of the kidneys in renal allograft recipients. Contrib Nephrol 1992, 100:254-268.
• [36]Levine E: Renal cell carcinoma in uremic acquired renal cystic disease: incidence, detection, and management. Urol Radiol 1992, 13(4):203-210.
• [37]Marple JT, MacDougall M, Chonko AM: Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol 1994, 4(12):1951-1956.
• [38]Ishikawa I, Saito Y, Asaka M, Tomosugi N, Yuri T, Watanabe M, Honda R: Twenty-year follow-up of acquired renal cystic disease. Clin Nephrol 2003, 59(3):153-159.
• [39]Fleming S: Renal cell carcinoma in acquired cystic kidney disease. Histopathology 2010, 56(3):395-400.
• [40]Gulanikar AC, Daily PP, Kilambi NK, Hamrick-Turner JE, Butkus DE: Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 1998, 66(12):1669-1672.
• [41]Silman AJ, Petrie J, Hazleman B, Evans SJ: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988, 47(12):988-992.
• [42]Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, et al.: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995, 87(7):524-530.
• [43]Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H: Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009, 101(6):374-383.
• [44]Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A: Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant 2009, 24(4):1238-1241.
• [45]Moyer VA: Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012, 157(2):120-134.
• [46]USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Betheda, MD; 2007.
• [47]Chertow GM, Paltiel AD, Owen WF, Lazarus JM: Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 1996, 156(12):1345-1350.
• [48]Gornik HL, Lazarus JM, Chertow GM: Cancer screening and detection in patients with end-stage renal disease. The International journal of artificial organs 1998, 21(9):495-500.
• [49]Holley JL: Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2007, 2(3):604-610.